@entity788 has the worst prognosis of all @entity5 with a dismal 5-year survival rate. Hence, there is a tremendous need for development of new and effective therapy for this @entity5 . In an earlier study we reported a potent antitumor activity of @entity70494 (AuriPE) against @entity788 . In addition, we have also reported that @entity10186 (bryo1) induces @entity1778 cells, but the effect of bryo1 has not been investigated in @entity788 . This is the first report where we demonstrate that bryo1 induces differentiation and potentiates the antitumor effect of AuriPE in a @entity1 @entity788 (PANC-1) xenograft model. A xenograft model was established by injecting the PANC-1 cells s.c. in @entity466 ( @entity466 ) @entity19 . After development of the s.c. @entity5 , @entity5 were dissected and small fragments were transplanted in vivo to new @entity466 @entity19 , with a success rate of 100% and a doubling time of 4.8 days. The @entity466 @entity19 xenograft model was used to test the in vivo differentiation effect of bryo1 and its efficacy when given alone or in combination with AuriPE. Sections from paraffin-embedded @entity5 excised from untreated (control) @entity466 @entity19 revealed typical poorly differentiated @entity420 . Interestingly, sections of s.c. @entity5 taken from bryo1-treated @entity19 revealed @entity189 that were much lower grade and less aggressive, and displayed prominent squamous and glandular differentiation. In this study, the @entity5 growth inhibition (T/C), activity score and cure rate for bryo1, AuriPE and bryo1+AuriPE were 80%, (+) and 0/4; 0.0%, (++++) and 3/5; and 0.0%, (++++) and 3/4, respectively. @entity19 treated with either AuriPE or bryo1+AuriPE were free of @entity5 for more than 150 days and were considered cured. The use of bryo1 as a novel differentiating agent and its combination with AuriPE should be further explored for the treatment of @entity420 .

@entity10186 induces differentiation and potentiates the antitumor effect of XXXX in a @entity1 @entity788 (PANC-1) xenograft model.

@entity1 :: ('9606', 'Species') :: ['human'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic tumors', 'Pancreatic cancer', 'pancreatic tumor'] @entity10186 :: ('MESH:C046785', 'Chemical') :: ['bryostatin 1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'tumors'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse', 'Mice'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas'] @entity70494 :: ('MESH:C105791', 'Chemical') :: ['Auristatin PE'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['differentiation of leukemia'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma of the pancreas'] @entity466 :: ('MESH:D016511', 'Disease') :: ['severe combined immune deficient', 'SCID']
@entity70494 :: (MESH:C105791,Chemical) :: ['Auristatin PE']
